Janssen Announces Drug Donation Program for HIV Treatment-Experienced Children - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Janssen Announces Drug Donation Program for HIV Treatment-Experienced Children


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 1

Janssen reported a pediatric HIV treatment donation program to improve access to the company’s approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa. At the 17th International Conference on AIDS and STIs in Africa, Ministries of Health (MOHs) in sub-Saharan Africa were invited to submit a formal Expression of Interest to participate in the charitable pediatric HIV treatment donation program.

Through this program, Janssen will donate its HIV medicines Prezista (darunavir) and Intelence (etravirine), including child-friendly formulations, free of charge to eligible countries with the clinical capacity and willingness to address second- and third-line pediatric HIV treatment. Each child enrolled will receive Janssen’s donated HIV medicines as needed until they turn 19 at which point they will be transitioned into the adult national HIV program or other designated by the national HIV program for continued treatment.

The donation program is intended to be a first step in a broader collaborative effort to build awareness, incite action, and advance learning around second- and third-line pediatric HIV treatment in sub-Saharan Africa. Janssen is working with the Elizabeth Glaser Pediatric AIDS Foundation, the Partnership for Supply Chain Management (PFSCM), and MAP International to fully maximize the impact and reach of this initiative.

The submission period for the Expression of Interest by country MOHs to participate in the drug donation initiative will run from Jan. 15, 2014 until Feb. 14, 2014. An independent, third-party review committee of international experts in pediatric HIV will review all applications to determine country eligibility to receive the donation.  Country approvals will be announced in March 2014. Countries interested in more information or submitting an Expression of Interest should visit: www.pedaids.org/treatmentdonation.

Source: Janssen

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here